

# Analysis of US Opioid Mortality and ER Visit Data

Version 1.2

[CDC Wonder + AHRQ HCUP-US Databases]

Richard A Lawhern, Ph.D +  
John Alan Tucker, Ph.D.\*

Updated April 7, 2019

+ Richard A Lawhern, Ph.D – Updated to Version 1.2 with revised opioid mortality data and graphics

\* John Alan Tucker, Ph.D. - Original data extraction, organization and Excel spreadsheet graphics for Version 1.0

# Objectives and Sources

- Assess trends, patterns in opioid prescriptions versus opioid-related mortality by US State
- Assess trends, patterns in Emergency Department admissions for opioid-related causes
- Sources
  - \* CDC Wonder Database
  - \* CDC Prescribing Data
  - \* Agency for Healthcare Research Quality  
HCUP-US Database
- Trends Checked in Organization for Economic Cooperation and Development (OECD = 34 industrialized countries)
- Data Current April 7, 2019

# Take-Away Conclusions

- There is no consistent cause and effect relationship between rates of opioid prescription versus rates of opioid-overdose-related deaths by US State.
- Deeper production restrictions on scheduled prescription opioids – either prescribed for patients or diverted – will not reduce opioid-overdose related deaths or opioid-related hospital admissions.

# Graphical Analysis of Overdose Rates by US State

# About Data Analysis


Excel™ spreadsheets offer “regression analysis” capabilities, to examine how strongly one set of data may be related to another. “R-Squared” is a mathematical measure of how well two groups of data “fit” with a model of the relationship between them.

In a strong relationship, R-Squared should be above 0.9. This means that the data “fit” closely around a “moving average” line. The smaller the value of R-Squared, the weaker is the “fit” and the weaker is the relationship.

In charts which follow, data on opioid-related overdoses from all sources (legal and illegal) and data on hospital and ER visits involving opioids of all kinds (legal and illegal) are compared with State-by-State rates of medical opioid prescriptions.


Computed R-squared for all of the data is so low and statistical splatter is so high that no consistent relationship can be detected. **Higher rates of prescription are *NOT* “causing” increased drug overdose deaths.** Other factors must be at work.

### Rxing Rate vs Opioid Related Deaths per 100,000 Population, By State, 2006




Opioid deaths per 100K population vs. prescriptions per 100 people by US State.  
Updated April 7, 2019

### Rxing Rate vs. Opioid Related Deaths per 100K Population By State, 2010



Opioid deaths per 100K population vs. prescriptions per 100 people by US State.  
Updated April 7, 2019

### Rxing Rate vs Opioid-Related Deaths per 100K Population, By State, 2016




Opioid related deaths per 100K Population vs. prescriptions per 100 people by US State.


Updated April 7, 2019



# Change in Opioid Deaths per 100K vs Change in Rxing, by State, 2010-2016




# Graphical Analysis of Hospital Visits vs Opioid Prescribing




Opioid Prescriptions per 100 people by US State vs. Opioid Related ER Visits per 100,000 population.

## Opioid-Related ER Visits vs. Opioid Rxing by State, 2015



Opioid Prescriptions per 100 people by US State vs.  
Opioid Related ER Visits per 100,000 population.


## Change in Rxing vs. Change in ER Visits by State 2010 to 2016



Change in prescribing vs. change in ER Visits by US State.  
Trend line = rise in mortality with fall in prescription rates

# Age Adjusted Opioid-Overdose Related Mortality by Year and Age

(CDC Wonder Database Apr 2, 2019)




Dataset: Multiple Cause of Death, 1999-2017

Narcotics Related (T40.0-T40.6) Accidental and Intentional Drug Overdose Deaths (X42, X62)

## Opioid Prescribing by Age Group \*


### Prescribing Rates per 100 Population by Age Range, 2016



\* Prescriptions/100 population over age 55 >300% higher than under age 20.

# One Opioid Crisis or Many?

## Prescribing Rate per 100 Population by Year - 6 US States 2006-2016




Prescribing rates vary by 3:1 across States, fall after 2010




# One Opioid Crisis or Many? (2)

Opioid-Related Mortality per 100K  
by Year - 6 US States 2006-2016



**2006-2012 OD-related mortality relatively stable.  
Rates vary .005% to .025% between six analyzed States.  
2012-2016 mortality rises sharply in some States, not in others.**

## OECD Countries - Overdose Deaths Vs. Opioid Defined Daily Doses



Organization of Economic Cooperation and Development – 34 industrialized countries. Wide “scatter”, **no consistent trends** for overdose deaths vs. average daily doses per million population.

# Observations on Opioid-Related Mortality by Age Group 1999-2017

- Age-adjusted mortality below age 14 or above age 84 unreliable due to small numbers
- Mortality rises for all age groups, but most sharply for age 15-24, 25-34, 35-44
- Mortality trends are closely similar under age 44
- Age-adjusted mortality for age 15-24 increases by ~600%, 1999-2017
- Age adjusted mortality above age 64 is lowest of any group, and relatively stable

## Observations (2)

- Opioid-Related Deaths/100K Population show no significant upward trend or correlation with prescribing rates
- For 2016, mortality trend *drops* in States with higher prescribing rates.
- Major mortality differences between US States suggest multiple factors and causes are operating.
- Something besides prescribing is going on – Possibly increased illegal street drugs, particularly Fentanyl, and patient suicides.

## Observations (3)

- 2017 US mortality rate attributed to opioid overdose is .0025% in seniors, compared to 0.018% in youth - and .007% in other developed countries.
- US mortality increase 1999-2016 is dominated by adolescents and adults under 55. However, highest rates of opioid prescription are among adults over age 50.
- Among 34 industrialized countries, opioid overdose rates show no trends versus daily opioid doses per million population.

## Observations (4)

**\* Prescribing rates are not a significant driver in either US overdose deaths or ER admission rates.**

# Source Notes (1)

- Prescribing Data – from CDC Prescribing Data Page
  - Prescribing data privatized after 2016. No longer publicly available without fee
- Mortality and Population – from CDC Wonder Database, Updated April 2, 2019
  - Data (deaths / 100,000) obtained by searching deaths by year and State using ICD codes for Narcotics Related (T40.0-T40.6) accidental and intentional Drug Overdose Deaths (X42, X62) within the UCD - Drug/Alcohol Induced Causes" module of "Underlying Cause of Death" database.
- Emergency Room Visits – Agency for Healthcare Research Quality
  - Data downloaded December 2017 as Excel spreadsheet. ER visits per 100K population in 35 states for ER visits and in 46 states for inpatients.
- Correlation of Prescribing With Mortality and ER Visits – Performed with Excel™ Spreadsheet Graphics Tools
- Year by Year Analysis of Overdose Deaths by Age Cohort
  - Searched CDC Wonder (1999-2017) by age (10 year intervals) and State, using the Underlying Cause of Death codes for accidental death or suicide (X42, X62) attributed to opioids (T40.0-T40.6)
- Organization for Economic Cooperation and Development (34 Nations)
  - Opioid Consumption data from [https://www.incb.org/incb/en/narcotic-drugs/Technical\\_Reports/2016/narcotic-drugs-technical-report-2016.htm](https://www.incb.org/incb/en/narcotic-drugs/Technical_Reports/2016/narcotic-drugs-technical-report-2016.htm).

# Source Notes (2)

- Opioid-Related ER Visits and Hospital Admissions Estimated by Diagnostic Codes (CDC Wonder)
  - Hospital inpatient stays and ER visits including opioid-related hospital use are identified by any diagnosis from a range of codes in the International Classification of Diseases, relating to legal and illegal opioids.  
  
ICD-9 prior to October 2015  
ICD-10-CM after October 2015
  - Rx and Admissions data are aggregated by drug type and medical diagnosis code. Adverse outcomes are not reliably tracked to diverted versus therapeutic use.



# Author Notes

- Richard A Lawhern, PhD is a technically trained non-physician healthcare writer and patient advocate, with 22 years experience in peer to peer social media support groups and medical literature analysis.
- John Alan Tucker, PhD is a research chemist and business analyst for Fortune 1000 financial services firms.
- Neither author has a personal financial interest in the findings or data of this presentation.